US HB7121 | 2021-2022 | 117th Congress

Status

Spectrum: Partisan Bill (Republican 9-0)
Status: Introduced on March 17 2022 - 25% progression, died in committee
Action: 2022-03-18 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

To require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Protecting our Pharmaceutical Supply Chain from China Act of 2022

Sponsors


History

DateChamberAction
2022-03-18HouseReferred to the Subcommittee on Health.
2022-03-17HouseReferred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2022-03-17HouseIntroduced in House

Same As/Similar To

SB2495 (Related) 2021-07-28 - Read twice and referred to the Committee on Finance.
SB3401 (Related) 2021-12-15 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Subjects


US Congress State Sources


Bill Comments

feedback